Title: Chief Operating Officer
Company: SOHM Inc.
Location: Bonita, California, United States
David C. Aguilar, PhD, chief operating officer at SOHM Inc., has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements and leadership in pharmacology.
Dr. Aguilar, a leader in pharmacology with a profound commitment to advancing drug development and gene editing technologies, has served as the chief operating officer at SOHM Inc. since 2023. As part of his responsibilities, he oversees corporate divisions and ensures the daily progress of operations. His role also includes attending meetings and guiding the company through a rebuilding phase.
Initially recruited to SOHM Inc. to develop a novel gene editing technology that has demonstrated effectiveness in creating cell therapies that target cancer, Dr. Aguilar has been focusing on advancing this technology. As such, he is reprogramming DNA using information related to human diseases and health to bring hope to individuals facing various health challenges.
Based in Chino Hills, California, SOHM Inc. is a growing pharmaceutical manufacturing and marketing company focusing on the rapidly growing health care sectors, such as nutraceuticals, cosmeceuticals and other major therapeutic segments. Before transitioning into his present role, Dr. Aguilar became a member of the board of advisers for SOHM Inc. starting in 2022.
In 2023, Dr. Aguilar also briefly held the role of sales manager for the West Coast at Particle Measuring Systems, a company based in Boulder, Colorado, specializing in contamination monitoring. He also excelled as the head of CMC at Kiromic Biopharma Inc., an allogeneic Gamma Delta T-cell therapy company headquartered in Houston, from 2021 to 2023.
Dr. Aguilar’s earlier roles included serving as a regenerative medicine consultant between 2018 and 2021 and as the chief executive officer at Exeligen Scientific Inc. in San Diego from 2015 to 2021, managing overall operations, research and development, marketing and more. Dr. Aguilar’s scientific expertise was previously honed as a scientist at Cellecta Inc. in Mountain View, California, in 2017 and, among other roles, as a contract scientist III at Thermo Fisher Scientific from 2014 to 2015.
Dr. Aguilar’s academic journey began with an Associate of Arts from Southwestern Community College District in 2000, followed by a Bachelor of Science in cell biology from the University of California (UC) San Diego in 2003. Subsequently, he earned a PhD in pharmacology from the University of Arizona in 2012. Dr. Aguilar’s education laid the foundation for his innovative work in pharmacology and gene editing.
In addition to his professional accomplishments, Dr. Aguilar holds several certifications that have bolstered his career trajectory. These include a minimum continuing legal education (MCLE) certification in technology and licensing from UC San Diego, a certificate in executive leadership from Stanford University, and recognition as a fellow in the life sciences by the National Academy of Education.
Dr. Aguilar’s dedication extends to his involvement in industry-related organizations, such as the Society of Toxicology. He also serves on the board of the American Association for Cancer Research.
Drawing significant inspiration from his wife, Kaoto, who holds a PhD in psychology, Dr. Aguilar aims to continue progressing by integrating artificial intelligence with patient data to identify the most effective drugs for each patient, ensuring optimal outcomes while maintaining a patient-first approach. Through his unwavering dedication to pharmacology and patient care, he continues to make significant strides in advancing medical treatments that improve lives globally.
For more information, please visit:
Contact Dr. Aguilar:
